Currently, telitacicept, a biologic agent approved by the National Medical Products Administration of China,[28] targets both BAFF and APRIL and has demonstrated significant efficacy in improving clinical scores in MG patients in a phase II clinical trial.[29] Based on these findings, we conducted a prospective clinical study at Peking University People's Hospital, enrolling 48 MG patients, who were divided into a telitacicept therapy group (n = 23) and a tacrolimus group (n = 25) (Figure 8B). The gene discussed is TNFSF13B; the disease is myasthenia gravis.